Cardiovascular disease: risk assessment and reduction, including lipid modification – updated guidance (CG181)
Updated recommendations include risk assessment for primary prevention (including using QRISK3 tool), use of cardioprotective diets (total and saturated fat intake <30% and <7% total energy intake respectively) and management of musculoskeletal adverse effects of statins.
Source:
National Institute for Health and Care Excellence
SPS commentary:
The Quality Standard for cardiovascular risk assessment and lipid modification (QS100) has been updated in conjunction, with updated quality statements for formal risk assessment (to use QRISK3) and review of side effects of high intensity statins.